trial acute coronary syndrome based on the RITA 3 interventional strategy in non-ST-elevation The cost-effectiveness of an early

http://heart.bmj.com/content/94/6/717.full.html Updated information and services can be found at: These include: Material Supplemental http://heart.bmj.com/content/suppl/2008/05/06/hrt.2007.127340.DC1.html References http://heart.bmj.com/content/94/6/717.full.html#related-urls Article cited in: http://heart.bmj.com/content/94/6/717.full.html#ref-list-1 This article cites 20 articles, 12 of which can be accessed free at:

[1]  Mark J Sculpher,et al.  Costs of an early intervention versus a conservative strategy in acute coronary syndrome. , 2008, International journal of cardiology.

[2]  Andrew Briggs,et al.  Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study , 2006, Heart.

[3]  L. Wallentin,et al.  5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study , 2006, The Lancet.

[4]  B. Gersh.  Early Invasive Versus Selectively Invasive Management for Acute Coronary Syndromesde Winter RJ, for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators (Academisch Medisch Centrum, Amsterdam; et al) N Engl J Med 353:1095-1104, 2005§ , 2006 .

[5]  P. Poole‐Wilson,et al.  5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial , 2005, The Lancet.

[6]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[7]  Mark J Sculpher,et al.  Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). , 2005, Journal of the American College of Cardiology.

[8]  M. Janzon.  Treatment strategies in unstable coronary artery disease : economic and quality of life evaluations , 2003 .

[9]  K. Fox,et al.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial , 2002, The Lancet.

[10]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[11]  P. Widimsky,et al.  Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. , 2002, European heart journal.

[12]  L. Levin,et al.  Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. , 2002, European heart journal.

[13]  C. Cannon,et al.  Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. , 2002, JAMA.

[14]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[15]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[16]  R. Kleiger,et al.  Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. , 1999, The New England journal of medicine.

[17]  W. O’Neill,et al.  A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. , 1998, Journal of the American College of Cardiology.

[18]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[19]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[20]  C. Cannon,et al.  One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. , 1995, Journal of the American College of Cardiology.

[21]  David Collett.  Modelling Survival Data in Medical Research , 1994 .